OPKO Health, Inc. (NASDAQ:OPK) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lessened its stake in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 42.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 856,738 shares of the biotechnology company's stock after selling 634,254 shares during the period. Assenagon Asset Management S.A. owned approximately 0.13% of OPKO Health worth $1,265,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in OPK. FMR LLC grew its holdings in shares of OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock valued at $32,000 after buying an additional 11,089 shares during the last quarter. Private Advisor Group LLC lifted its position in OPKO Health by 242.7% in the 3rd quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company's stock valued at $53,000 after acquiring an additional 25,000 shares in the last quarter. Orion Portfolio Solutions LLC purchased a new stake in OPKO Health during the 3rd quarter valued at $45,000. Algert Global LLC bought a new stake in shares of OPKO Health in the 2nd quarter worth $44,000. Finally, World Investment Advisors LLC purchased a new position in shares of OPKO Health in the third quarter worth $61,000. Hedge funds and other institutional investors own 64.63% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on OPK shares. HC Wainwright reaffirmed a "buy" rating and issued a $3.00 target price on shares of OPKO Health in a research report on Wednesday, January 8th. Barrington Research reaffirmed an "outperform" rating and issued a $2.25 price objective on shares of OPKO Health in a report on Friday, November 8th. Finally, StockNews.com downgraded OPKO Health from a "hold" rating to a "sell" rating in a report on Wednesday, January 15th.

Insider Activity

In other news, CEO Phillip Md Et Al Frost acquired 100,000 shares of the company's stock in a transaction that occurred on Thursday, November 14th. The stock was purchased at an average price of $1.62 per share, with a total value of $162,000.00. Following the completion of the acquisition, the chief executive officer now owns 211,612,405 shares of the company's stock, valued at $342,812,096.10. This trade represents a 0.05 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have bought a total of 1,954,255 shares of company stock worth $2,985,105 over the last quarter. 47.26% of the stock is currently owned by corporate insiders.

OPKO Health Stock Performance

OPK traded down $0.01 on Friday, reaching $1.48. 1,336,926 shares of the stock were exchanged, compared to its average volume of 2,601,241. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The company's 50-day moving average price is $1.53 and its 200 day moving average price is $1.51. The firm has a market capitalization of $1.01 billion, a PE ratio of -7.79 and a beta of 1.63. OPKO Health, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $1.76.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.13. The company had revenue of $173.60 million for the quarter, compared to the consensus estimate of $181.32 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. During the same period last year, the firm earned ($0.11) EPS. As a group, sell-side analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.